Source:http://linkedlifedata.com/resource/pubmed/id/16316644
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1-3
|
pubmed:dateCreated |
2005-12-12
|
pubmed:abstractText |
The insulinotropic activity of KCP256 [(R)-8-benzyl-2-cyclopentyl-7, 8-dihydro-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one hydrochloride] was examined using MIN6 cells (a pancreatic beta-cell line) and pancreatic islets isolated from rats. Unlike sulfonylurea anti-diabetic drugs, KCP256 dose-dependently (0.1-10 microM) enhanced insulin secretion from MIN6 cells and its insulinotropic effect was exerted only at high concentrations of glucose (8.3-22 mM) but not at low concentrations of glucose (3.3-5.5 mM). Furthermore, the action mechanism of KCP256 was different because, unlike sulfonylurea drugs, KCP256 did not displace the binding of [3H]glibenclamide, and did not inhibit the 86Rb+ efflux nor K(ATP) channel activity. In isolated islets, KCP256 also enhanced insulin secretion in a dose- and a glucose-concentration-dependent manner. Plasma levels of insulin after glucose challenge in KCP256-administrated rats were higher than those in vehicle-administrated animals, indicating that KCP256 can enhance insulin secretion in vivo. Since the insulinotropic activity of KCP256 only occurs at high concentrations of glucose, this novel drug may exhibit a decreased risk of drug-induced hypoglycemia compared with sulfonylurea drugs when treating patients with diabetes.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose,
http://linkedlifedata.com/resource/pubmed/chemical/Glucose,
http://linkedlifedata.com/resource/pubmed/chemical/Hypoglycemic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Imidazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin,
http://linkedlifedata.com/resource/pubmed/chemical/Purines,
http://linkedlifedata.com/resource/pubmed/chemical/Purinones
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0014-2999
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
28
|
pubmed:volume |
528
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
176-82
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:16316644-Animals,
pubmed-meshheading:16316644-Blood Glucose,
pubmed-meshheading:16316644-Cell Line, Tumor,
pubmed-meshheading:16316644-Dose-Response Relationship, Drug,
pubmed-meshheading:16316644-Drug Synergism,
pubmed-meshheading:16316644-Glucose,
pubmed-meshheading:16316644-Glucose Tolerance Test,
pubmed-meshheading:16316644-Hypoglycemic Agents,
pubmed-meshheading:16316644-Imidazoles,
pubmed-meshheading:16316644-Insulin,
pubmed-meshheading:16316644-Islets of Langerhans,
pubmed-meshheading:16316644-Male,
pubmed-meshheading:16316644-Purines,
pubmed-meshheading:16316644-Purinones,
pubmed-meshheading:16316644-Rats,
pubmed-meshheading:16316644-Rats, Wistar
|
pubmed:year |
2005
|
pubmed:articleTitle |
Glucose concentration-dependent potentiation of insulin secretion by a new chemical entity, KCP256.
|
pubmed:affiliation |
Drug Discovery Research Laboratories, Pharmaceutical Research Center, Kyowa Hakko Kogyo Co., Ltd., 1188 Shimotogari, Nagaizumi-cho, Shizuoka, Japan. kiyotoshi.mori@kyowa.co.jp
|
pubmed:publicationType |
Journal Article,
In Vitro
|